Key result
Long-term antithrombotics post-PFO closure linked to more bleeding versus short-term therapy, with similar embolic risk.
Why the study?
Long-term data on patent foramen ovale closure beyond 10 years are rare, and the comparative efficacy of different post-procedural antithrombotic regimens remains unclear.
Does short-term post-procedural antithrombotic treatment compared to long-term treatment reduce bleeding without increasing recurrent embolic events in patients following PFO closure?
Cohort (n=301)
Does short-term post-procedural antithrombotic treatment compared to long-term treatment reduce bleeding without increasing recurrent embolic events in patients following PFO closure?
Over a 15-year follow-up after PFO closure, a limited post-procedural antithrombotic regimen is as effective as long-term therapy for preventing recurrent embolic events, with potentially less bleeding.
Answers are grounded in this paper and cite their sources.
May favor short-term antithrombotic therapy after PFO closure to limit bleeding; leaves open optimal duration for randomized confirmation.
BACKGROUND: Patent foramen ovale (PFO) has been identified as a conduit for paradoxical embolism causing stroke or transient ischemic attack (TIA). Long-term data of PFO closure beyond 10 years are rare. AIMS: We aimed to report the very long-term outcomes of PFO closure and compare the efficacy of different post?procedural antithrombotic treatment (AT). METHODS: Very long-term outcomes of a previously reported cohort of patients undergoing PFO closure between May 2004 and January 2013 were reviewed. Outcomes, including recurrent stroke or TIA, bleeding, venous thromboembolism (VTE), newly diagnosed atrial fibrillation (AF), and all-cause death, were adjudicated. The cohort was further stratified into short- and long-term post-procedural AT groups. Propensity-score matching was performed to adjust for differences in baseline characteristics across subgroups. RESULTS: Three hundred and one patients were included in the analysis. Median follow-up duration was 15.0 [95% confidence interval 14.7-15.3] years. Stroke and TIA occurred in 3.4% (0.27 per 100 patient-year) and 6.2% (0.46 per 100 patient-year), respectively. Bleeding and VTE were noted in 3.8% and 6.5%. 9.6% of patients (0.71 per 100 patient-year) developed AF. Thirty patients (0.70 per 100 patient-year) died. Patients receiving long-term AT (a single antiplatelet in > 85% of the population) experienced more bleeding and major bleeding events (log-rank p = 0.03 and 0.02, respectively), and had a tendency toward more frequent bleeding after propensity score matching (p = 0.09). Other outcome events were similar between subgroups. CONCLUSION: Benefits from PFO closure persist over the long term. A limited post-closure AT regimen is equally effective in preventing recurrent embolic events and is associated with potentially less bleeding.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2026) conducted a cohort in Cryptogenic embolism with patent foramen ovale (n=301). Long-term post-procedural antithrombotic treatment vs. Short-term post-procedural antithrombotic treatment was evaluated on Recurrent stroke or TIA, bleeding, venous thromboembolism, atrial fibrillation, and all-cause death (p=0.03). Long-term antithrombotic treatment after PFO closure was associated with more bleeding events compared to short-term treatment, with similar rates of recurrent embolic events.
Synapse has enriched 10 related papers. Consider them for comparative context: